Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis
ConclusionHDR-BT has a high safety profile and good RFS benefit for salvage treatment of radiorecurrent prostate cancer. In terms of RFS, whole-gland irradiation with multiple fractions seems to be better than focal gland irradiation with fewer fractions, while short TRS and younger age are good prognostic factors. In v iew of the low level of evidence in the included studies and the large heterogeneity of each study, these conclusions still need to be confirmed by randomized controlled trials.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Austria Health | Brachytherapy | Cancer | Cancer & Oncology | Environmental Health | Gastroenterology | Prostate Cancer | Statistics | Study | Toxicology